The immune system is a highly regulated and balanced system made up of two fundamental parts: the innate immune system and the adaptive immune system. These two systems work closely together, taking on different tasks to efficiently fight foreign substances in the body. However, imbalanced immune systems can result in a range of different autoimmune and inflammatory diseases.

Existing treatment regimens aim to suppress the overactive immune response, but more frequently come at very high costs for patients with autoimmune diseases, including life-impacting side effects. We believe now is the time to shift these very generalized approaches to a more targeted, science-driven therapy.

Our novel pipeline and next-generation platform consist of small molecule new chemical entities that potently and selectively modulate scientifically validated targets playing a driving role in well-defined immune-inflammatory diseases. We have access to both peripherally acting and brain penetrating molecules, which allow us to introduce potential therapies that may have an impact in restoring immune homeostasis in patients with autoimmune, inflammatory, neurodegenerative, and other high-impact diseases.